Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.

Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP.

J Clin Pharmacol. 1993 Mar;33(3):226-9.

PMID:
8463436
2.

Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors.

Bargossi AM, Grossi G, Fiorella PL, Gaddi A, Di Giulio R, Battino M.

Mol Aspects Med. 1994;15 Suppl:s187-93.

PMID:
7752830
3.

Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin.

Lintott CJ, Scott RS, Sutherland WH, Bremer J.

Aust N Z J Med. 1993 Aug;23(4):381-6.

PMID:
8240151
4.

Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients.

Miyake Y, Shouzu A, Nishikawa M, Yonemoto T, Shimizu H, Omoto S, Hayakawa T, Inada M.

Arzneimittelforschung. 1999 Apr;49(4):324-9.

PMID:
10337451
5.

Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.

Mortensen SA, Leth A, Agner E, Rohde M.

Mol Aspects Med. 1997;18 Suppl:S137-44.

PMID:
9266515
6.
8.

Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA.

Passi S, Stancato A, Aleo E, Dmitrieva A, Littarru GP.

Biofactors. 2003;18(1-4):113-24.

PMID:
14695926
9.

Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.

Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, Salvatore T, Corigliano G, Agrusta M, De Simone G, Gaeta I, Oliviero B, Torella R.

Diabetes Obes Metab. 2000 Dec;2(6):355-62.

PMID:
11225965
10.

Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.

Joles J, Willekes-Koolschijn N, Koomans H, Van Tol A, Geelhoed-Mieras T, Crommelin D, Van Bloois L, Krajnc-Franken M, Cohen L, Griffioen M, et al.

Lab Anim. 1992 Oct;26(4):269-80.

PMID:
1447905
11.

Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.

Cohen LH, van Vliet A, Roodenburg L, Jansen LM, Griffioen M.

Biochem Pharmacol. 1993 Jun 9;45(11):2203-8. Erratum in: Biochem Pharmacol 1993 Sep 14;46(6):1101.

PMID:
8517861
12.

Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study.

Mabuchi H, Nohara A, Kobayashi J, Kawashiri MA, Katsuda S, Inazu A, Koizumi J; Hokuriku Lipid Research Group.

Atherosclerosis. 2007 Dec;195(2):e182-9. Epub 2007 Aug 6.

PMID:
17681347
13.

Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.

Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ.

J Clin Pathol. 1993 Nov;46(11):1055-7.

14.

Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits.

Fukami M, Maeda N, Fukushige J, Kogure Y, Shimada Y, Ogawa T, Tsujita Y.

Res Exp Med (Berl). 1993;193(5):263-73.

PMID:
8278673
15.

Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.

Stalenhoef AF, Lansberg PJ, Kroon AA, Kortmann B, De Haan AF, Stuyt PM, Kastelein JJ.

J Intern Med. 1993 Jul;234(1):77-82.

PMID:
8326293
16.

Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.

Naoumova RP, Marais AD, Mountney J, Firth JC, Rendell NB, Taylor GW, Thompson GR.

Atherosclerosis. 1996 Jan 26;119(2):203-13.

PMID:
8808497
17.

Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

Bargossi AM, Battino M, Gaddi A, Fiorella PL, Grossi G, Barozzi G, Di Giulio R, Descovich G, Sassi S, Genova ML, et al.

Int J Clin Lab Res. 1994;24(3):171-6.

PMID:
7819598
18.
19.
20.

Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.

Branchi A, Rovellini A, Fiorenza AM, Sommariva D.

Int J Clin Pharmacol Ther. 1995 Jun;33(6):345-50.

PMID:
7582386

Supplemental Content

Support Center